Surajit Mahapatra

Dapagliflozin impairs renal epithelial innate immunity and facilitates uropathogenic E. coli infection in diabetes

Risk of pyelonephritis is very high among patients with diabetes. During diabetes, the oral antidiabetic drug, dapagliflozin (DAPA) is commonly prescribed for its well-recognized renoprotective effects. Although DAPA lowers renal glucose reabsorption, it significantly increases u...